Jiangsu Hengrui Medicine Co., Ltd.
600276.SS
$-0.09
Change (1 day)
$7.90
Year High
$5.11
Year Low
Categories
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 842.58 M | -2,838,978,755 | 377.88 M | 6.01 B | 4.3 B |
| 2022 | 1.15 B | -1,888,567,620 | 541.38 M | 5.82 B | 4.25 B |
| 2021 | 945.45 M | -1,851,259,346 | 507.4 M | 5.39 B | 4.15 B |
| 2020 | 1.12 B | -1,263,966,890 | 541.48 M | 4.77 B | 3.85 B |
| 2019 | 746.42 M | -635,040,557 | 359.69 M | 3.78 B | 3.06 B |